title: [Tobacco use prevention and cessation in the dental practice].
abstract: This is the fourth part of a series of publications from the Swiss task force named "Smoking--intervention in the private dental office" on the topic "tobacco use and dental medicine". It presents the implementation of tobacco use prevention and cessation in the dental practice. Next to the optimal performance of plaque control, tobacco use cessation has become the most important measure for the treatment of periodontal diseases. In contrast to general medicine practice, the dental practice team is seeing its patients regularly and is therefore capable of helping their patients quit tobacco use. Tobacco dependence consists of both a physical and a psychological dependence. Therefore, the combination of pharmacotherapy with behavior change counseling is recommended. The use of brief Motivational Interviewing (BMI) for tobacco use short interventions in the dental practice appears to be suitable. Nicotine replacement therapy (NRT) is the treatment of choice for the dental practice team because both Varenicline and Bupropion SR have to be prescribed by physicians.
authors.affiliation: Dept. of Periodontics and Oral Medicine School of Dentistry, University of Michigan, 1011 N. University Avenue, Ann Arbor 48109, USA. ramseier@umich.edu
authors.forename: Christoph A
authors.initials: CA
authors.lastname: Ramseier
authors.forename: Michael M
authors.initials: MM
authors.lastname: Bornstein
authors.forename: Ulrich P
authors.initials: UP
authors.lastname: Saxer
authors.forename: Karl
authors.initials: K
authors.lastname: Klingler
authors.forename: Clemens
authors.initials: C
authors.lastname: Walter
mesh_terms: D001521:Behavior Therapy / Q000379:methods; D001552:Benzazepines / Q000627:therapeutic use; D016642:Bupropion / Q000627:therapeutic use; D003812:Dentist-Patient Relations; D006284:Health Plan Implementation; D006801:Humans; D007406:Interview, Psychological / Q000379:methods; D009062:Mouth Neoplasms / Q000209:etiology; D018722:Nicotinic Agonists / Q000627:therapeutic use*; D009765:Obesity / Q000523:psychology; D010518:Periodontitis / Q000209:etiology; D024382:Professional Role; D011810:Quinoxalines / Q000627:therapeutic use; D020377:Self Efficacy; D011795:Surveys and Questionnaires; D020340:Tobacco Use Cessation / Q000379:methods / Q000523:psychology; D014029:Tobacco Use Disorder / Q000150:complications / Q000628:therapy*; D000068580:Varenicline; D015430:Weight Gain
chemical_list: D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D000068580:Varenicline